Development
Boston Scientific Corporation
BSX
$102.83
$0.400.39%
NYSE
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 12.29% | 9.47% | 8.69% | 7.26% | 6.68% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 12.29% | 9.47% | 8.69% | 7.26% | 6.68% |
| Cost of Revenue | 9.69% | 7.45% | 6.41% | 6.96% | 6.46% |
| Gross Profit | 13.48% | 10.40% | 9.74% | 7.40% | 6.78% |
| SG&A Expenses | 14.82% | 10.29% | 9.45% | 6.25% | 3.69% |
| Depreciation & Amortization | 3.24% | 3.02% | 4.63% | 7.16% | 8.37% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.04% | 8.05% | 7.56% | 6.74% | 5.81% |
| Operating Income | 18.79% | 17.02% | 14.71% | 10.00% | 11.46% |
| Income Before Tax | 74.04% | 116.51% | 36.87% | 57.49% | 5.75% |
| Income Tax Expenses | -11.09% | 203.76% | 172.27% | 438.78% | 1,094.59% |
| Earnings from Continuing Operations | 127.94% | 88.06% | 3.17% | 11.36% | -32.95% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 128.08% | 88.06% | 3.17% | 11.36% | -32.95% |
| EBIT | 18.79% | 17.02% | 14.71% | 10.00% | 11.46% |
| EBITDA | 13.95% | 12.28% | 10.66% | 7.96% | 8.64% |
| EPS Basic | 140.27% | 97.03% | 3.26% | 11.65% | -35.17% |
| Normalized Basic EPS | 36.52% | 46.17% | 39.30% | 36.57% | 4.59% |
| EPS Diluted | 139.95% | 97.63% | 4.10% | 12.13% | -35.13% |
| Normalized Diluted EPS | 36.39% | 46.09% | 39.34% | 36.76% | 4.77% |
| Average Basic Shares Outstanding | 1.57% | 1.14% | 0.70% | 0.56% | 0.58% |
| Average Diluted Shares Outstanding | 1.66% | 1.17% | 0.64% | 0.41% | 0.41% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -0.78% | -0.60% | -0.03% | -0.10% | 0.49% |